Vyne Therapeutics Inc (VYNE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.76 Million) by net assets ($27.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Vyne Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Vyne Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Vyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vyne Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Vyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyne Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lakes Oil NL
AU:LKO
|
0.000x |
|
Inalways
TWO:5398
|
-0.012x |
|
Tontek Design Technology Ltd
TWO:5487
|
0.022x |
|
Adler Group SA
XETRA:ADJ
|
0.314x |
|
De.Mem Ltd
AU:DEM
|
0.064x |
|
CCID Consulting Company Limited
F:CCX
|
N/A |
|
Sungmoon Elect
KO:014910
|
0.013x |
|
NextTrip Inc
NASDAQ:NTRP
|
-0.316x |
Annual Cash Flow Conversion Efficiency for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Vyne Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Vyne Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.77 Million | $-33.12 Million | -1.193x | -82.91% |
| 2024-12-31 | $52.09 Million | $-33.97 Million | -0.652x | -128.39% |
| 2023-12-31 | $88.73 Million | $-25.34 Million | -0.286x | +69.48% |
| 2022-12-31 | $31.20 Million | $-29.20 Million | -0.936x | +19.25% |
| 2021-12-31 | $48.64 Million | $-56.37 Million | -1.159x | +68.30% |
| 2020-12-31 | $37.49 Million | $-137.08 Million | -3.656x | -284.75% |
| 2019-12-31 | $68.51 Million | $-65.10 Million | -0.950x | -134.94% |
| 2018-12-31 | $130.38 Million | $-52.73 Million | -0.404x | -181.67% |
| 2017-12-31 | $-57.03 Million | $-28.25 Million | 0.495x | +536.45% |
| 2016-12-31 | $-29.44 Million | $-2.29 Million | 0.078x | -70.32% |
| 2015-12-31 | $-15.95 Million | $-4.18 Million | 0.262x | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more